葡萄膜炎的医学治疗——当前趋势。
Medical management of uveitis - current trends.
机构信息
Department of Uvea and Ocular Inflammation, Vittala International Institute of Ophthalmology, Bangalore, Karnataka, India.
出版信息
Indian J Ophthalmol. 2013 Jun;61(6):277-83. doi: 10.4103/0301-4738.114099.
Abstract
Uveitis is a challenging disease to treat. Corticosteroids have been used in the treatment of uveitis for many years. Immunosuppressives are gaining momentum in recent years in the treatment of uveitis. In this article we present an overview of current treatment of uveitis and the major breakthroughs and advances in drugs and ocular drug delivery systems in the treatment of uveitis.
摘要
葡萄膜炎的治疗具有挑战性。皮质类固醇激素在葡萄膜炎的治疗中已经使用了很多年。近年来，免疫抑制剂在葡萄膜炎的治疗中也逐渐受到重视。本文对目前葡萄膜炎的治疗方法进行综述，并对治疗葡萄膜炎的药物和眼部药物递送系统的主要突破和进展进行概述。
相似文献
1
Medical management of uveitis - current trends.
Indian J Ophthalmol. 2013 Jun;61(6):277-83. doi: 10.4103/0301-4738.114099.
2
HLA-B27-associated uveitis: overview and current perspectives.
Curr Opin Ophthalmol. 2003 Dec;14(6):378-83. doi: 10.1097/00055735-200312000-00010.
3
Editorial: Immunosuppressive treatment for uveitis.
Br J Ophthalmol. 1975 Aug;59(8):395-6. doi: 10.1136/bjo.59.8.395.
4
Road to remission: a comprehensive review of therapy in uveitis.
Expert Opin Investig Drugs. 2011 Nov;20(11):1497-515. doi: 10.1517/13543784.2011.617741. Epub 2011 Sep 21.
5
Recent developments in the treatment of uveitis: an update.
Expert Opin Investig Drugs. 2009 May;18(5):609-16. doi: 10.1517/14728220902852570.
6
Treatment of autoimmune uveitis.
Ann N Y Acad Sci. 1993 Nov 30;696:307-18. doi: 10.1111/j.1749-6632.1993.tb17166.x.
7
Developments in the treatment of uveitis.
Expert Opin Investig Drugs. 2002 Jan;11(1):59-67. doi: 10.1517/13543784.11.1.59.
8
New Immunosuppressive Therapies in Uveitis Treatment.
Int J Mol Sci. 2015 Aug 11;16(8):18778-95. doi: 10.3390/ijms160818778.
9
Non-Infectious Uveitis: Optimising the Therapeutic Response.
Drugs. 2016 Jan;76(1):27-39. doi: 10.1007/s40265-015-0502-y.
10
Treatment of chronic non-infectious uveitis and scleritis.
Swiss Med Wkly. 2019 Mar 10;149:w20025. doi: 10.4414/smw.2019.20025. eCollection 2019 Feb 25.
引用本文的文献
1
Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study).
J Ophthalmic Inflamm Infect. 2025 Jul 22;15(1):56. doi: 10.1186/s12348-025-00514-5.
2
Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies.
Eye (Lond). 2024 Jul;38(10):1845-1854. doi: 10.1038/s41433-024-03057-6. Epub 2024 Apr 10.
3
Bilateral Acute Retinal Necrosis Treated With Antivirals and Corticosteroids.
Cureus. 2023 Oct 21;15(10):e47427. doi: 10.7759/cureus.47427. eCollection 2023 Oct.
4
Oral 5-aminolevulinic acid combined with sodium ferrous citrate prevents blood-aqueous barrier breakdown after anterior chamber paracentesis in healthy beagle dogs.
J Vet Med Sci. 2023 Dec 6;85(12):1257-1260. doi: 10.1292/jvms.23-0347. Epub 2023 Oct 24.
5
Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.
Adv Drug Deliv Rev. 2023 Jul;198:114869. doi: 10.1016/j.addr.2023.114869. Epub 2023 May 10.
6
Clinical relationship between dry eye disease and uveitis: a scoping review.
J Ophthalmic Inflamm Infect. 2023 Jan 30;13(1):2. doi: 10.1186/s12348-022-00323-0.
7
Ocular Cyclopentolate: A Mini Review Concerning Its Benefits and Risks.
Clin Ophthalmol. 2022 Nov 15;16:3753-3762. doi: 10.2147/OPTH.S388982. eCollection 2022.
8
Microemulsions as Lipid Nanosystems Loaded into Thermoresponsive In Situ Microgels for Local Ocular Delivery of Prednisolone.
Pharmaceutics. 2022 Sep 19;14(9):1975. doi: 10.3390/pharmaceutics14091975.
9
Inhibiting TLR7 Expression in the Retinal Pigment Epithelium Suppresses Experimental Autoimmune Uveitis.
Front Immunol. 2022 Jan 5;12:736261. doi: 10.3389/fimmu.2021.736261. eCollection 2021.
10
Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis.
Front Med (Lausanne). 2021 Sep 16;8:737256. doi: 10.3389/fmed.2021.737256. eCollection 2021.
本文引用的文献
1
New treatment options for noninfectious uveitis.
Dev Ophthalmol. 2012;51:134-61. doi: 10.1159/000336338. Epub 2012 Apr 17.
2
Biologic agents in inflammatory eye disease.
J Ophthalmic Vis Res. 2011 Oct;6(4):309-16.
3
Biological agents for the treatment of uveitis.
Expert Opin Biol Ther. 2012 Mar;12(3):311-28. doi: 10.1517/14712598.2012.658366.
4
Efficacy and potential complications of difluprednate use for pediatric uveitis.
Am J Ophthalmol. 2012 May;153(5):932-8. doi: 10.1016/j.ajo.2011.10.008. Epub 2012 Jan 20.
5
Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis.
Ophthalmology. 2012 Jan;119(1):66-73. doi: 10.1016/j.ophtha.2011.07.006. Epub 2011 Nov 23.
6
Difluprednate for inflammatory eye disorders.
Drugs Today (Barc). 2011 May;47(5):327-33. doi: 10.1358/dot.2011.47.5.1590791.
7
Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment.
Am J Ophthalmol. 2011 Nov;152(5):857-63.e2. doi: 10.1016/j.ajo.2011.05.004. Epub 2011 Jul 26.
8
Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate.
Arch Ophthalmol. 2011 May;129(5):667-8. doi: 10.1001/archophthalmol.2011.82.
9
Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
Rheumatology (Oxford). 2011 Aug;50(8):1390-4. doi: 10.1093/rheumatology/ker107. Epub 2011 Mar 4.
10
Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.
Clin Infect Dis. 2011 Mar 1;52(5):648-53. doi: 10.1093/cid/ciq204. Epub 2011 Jan 16.
Zotero 插件